Your session is about to expire
← Back to Search
Proton Beam Radiation Therapy for Brain Tumor
Study Summary
This trial is testing how well 18F-DOPA-PET/MRI works in imaging elderly patients with newly diagnosed grade IV malignant glioma or glioblastoma during planning for a short course of proton beam radiation therapy.
- Glioblastoma
- Malignant Glioma
Timeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Trial Design
Find a Location
Who is running the clinical trial?
Media Library
- You have been diagnosed with a type of brain tumor called glioma, ranging from grades I to III.You are currently taking Avastin for another medical condition.If you are taking any of these medications - amoxapine, amphetamine, benztropine, buproprion, buspirone, cocaine, mazindol, methamphetamine, methylphenidate, norephedrine, phentermine, phenylpropanolamine, selegiline, paroxetine, citalopram, or sertraline - please let us know on the study form.
- Group 1: Treatment (18F-DOPA, PET/MRI, PET/CT, temozolomide)
- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Frequently Asked Questions
What potential hazards arise from the administration of Temozolomide?
"Based on the available evidence, Temozolomide's safety was estimated to be a 2. This is due to it being in the Phase 2 trial stage, indicating that there is some data supporting its security but none concerning efficacy."
Are there any other scientific experiments involving Temozolomide that have been completed?
"Currently, 207 scientific investigations into Temozolomide are being executed; 24 of them inhabit Phase 3. The majority of occurrences can be observed in Seoul and Songpa, but the drug is also being studied at 4752 locations worldwide."
Is this study pioneering in its approach?
"According to the databases, there are 207 live studies for Temozolomide that span 36 countries and 935 cities. This medication has been monitored since 2002 when Schering-Plough conducted a Phase 2 study with 60 participants. Since then, 623 trials have concluded their research."
For which conditions is Temozolomide a common remedy?
"Nitrosourea-based treatments are often treated with temozolomide. This compound can also be beneficial in the management of refractory directives, advance mycosis fungoides, and intractable neuroblastoma."
What is the current enrollment size for this clinical trial?
"This clinical trial is no longer enrolling participants. It was first posted on March 28th 2019 and the last edits were made September 20th 2022. At present, there are 707 trials researching glioblastoma and 207 trials with Temozolomide which have open recruitment periods."
Are there any slots available to join this experiment?
"At this moment, no further patients are being sought for enrollment. This trial was initially posted on March 28th 2019 and finalized its updates in September 20th 2022. If you're looking for other studies related to glioblastoma or Temozolomide, there are currently 707 and 207 active trials respectively."
Share this study with friends
Copy Link
Messenger